Black Hawk Acquisition (BKHA) vs VivoSim Labs (VIVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Black Hawk Acquisition is the larger company by market cap ($7.7 million vs $5.3 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BKHA | VIVS |
|---|---|---|
| Share price | $1.85 | $0.2608 |
| Market cap | $7.68M | $5.29M |
| 1-day change | -71.45% | -10.53% |
| P/E ratio (TTM) | 5.61 | — |
| EPS (TTM) | $0.33 | $-3.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $131.00K |
| Revenue growth (YoY) | — | -9.03% |
| Net income (latest FY) | $1.33M | $-13.84M |
| Gross margin | — | 100.00% |
| Operating margin | — | -8768.70% |
| Net margin | — | -10567.18% |
| 52-week high | $23.00 | $3.40 |
| 52-week low | $1.75 | $0.12 |
| Distance from 52-week high | -91.96% | -92.33% |
| Average volume | 101.40K | 15.96M |
| Shares outstanding | 4.15M | 20.28M |
| Employees | — | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Hawk Acquisition
BKHA stock →Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About VivoSim Labs
VIVS stock →VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
BKHA vs VIVS FAQ
Which is bigger, Black Hawk Acquisition or VivoSim Labs?
Black Hawk Acquisition (BKHA) is larger, with a market capitalization of $7.68M compared with $5.29M for VivoSim Labs (VIVS).
Are Black Hawk Acquisition and VivoSim Labs in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.